Stem Cell Selection by TGF-β1 Secretion for Enhanced Cartilage Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for arthritis, including medications and surgical interventions, are inadequate in effectively preventing joint wear and have significant side effects, while cell therapy lacks quality control for optimal cartilage regeneration.
Innovation Solution
A method for selecting stem cells with enhanced cartilage differentiation capability by measuring TGF-β1 secretion in early passages, isolating and culturing stem cells with high TGF-β1 concentration, and using them to produce a cell therapy product for arthritis treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are used for cartilage regeneration therapy, then cartilage differentiation capability is improved, but quality control and selection precision are insufficient
Solution Approach 1:
The patent replaces mechanical/physical cell counting methods with a biochemical measurement system that quantifies TGF-β1 protein secretion levels. This substitution enables precise identification and selection of stem cells with high cartilage differentiation potential based on their secretory activity rather than mere presence or quantity.
Solution Approach 2:
The patent introduces TGF-β1 as an intermediary marker that mediates between the stem cell's differentiation potential and the measurable output. By measuring TGF-β1 secretion levels, the patent creates a reliable proxy indicator that connects the abstract concept of differentiation capability to a quantifiable biochemical parameter.
2Object-affected harmful factors
If existing arthritis treatments are used, then symptom relief is achieved, but joint wear prevention is insufficient and side effects occur
Solution Approach 1:
The patent converts the previously harmful effect of uncontrolled TGF-β1 secretion into a beneficial selection criterion. By measuring and selecting for high TGF-β1 secretion, the patent transforms what could be an uncontrolled variable into a controlled therapeutic advantage, enabling cells to be selected specifically for their cartilage-regenerating capacity.
Solution Approach 2:
The patent changes the parameter of TGF-β1 concentration from an uncontrolled biological variable to a controlled selection criterion. By establishing a threshold value (e.g., >1046.7 pg/1x10^5 cells) for TGF-β1 secretion, the patent transforms qualitative cell heterogeneity into a quantifiable selection parameter that enables consistent therapeutic outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces a cell therapy product with improved cartilage regeneration efficacy, effectively treating and preventing arthritis by using stem cells with high TGF-β1 secretion capability.
Implementation Method 1
measuring the concentration of TGF-β1 within a culture of stem cells
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention pertains to a method for selecting stem cells with enhanced cartilage differentiation capability, a cell therapy product comprising the stem cells selected by the selection method, and a production method therefor.